F. Dreyfus

R. Benarous, E. Rouer, F. Dreyfus, 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Expression of the c-mpl proto-oncogene in human hematologic malignancies.

V. Ribrag, F. Viguié, F. Dreyfus, 1993, Blood.

Spontaneous and Fas-induced apoptosis of low-grade MDS erythroid precursors involves the endoplasmic reticulum

E. Solary, C. Garrido, C. Lacombe, 2008, Leukemia.

Ineffective erythropoiesis in myelodysplastic syndromes: correlation with Fas expression but not with lack of erythropoietin receptor signal transduction

C. Lacombe, P. Mayeux, D. Bouscary, 1999, British journal of haematology.

Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy

J. Tamburini, C. Roux, S. Choquet, 2008, Leukemia & lymphoma.

High levels of CD34+CD38low/−CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang (GOELAMS) study

J. Tamburini, S. Manenti, C. Récher, 2011, Haematologica.

Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

P. Fenaux, M. Fontenay, Sophie Park, 2016, Haematologica.

Analysis of megakaryocyte growth and development factor (thrombopoietin) effects on blast cell and megakaryocyte growth in myelodysplasia.

N. Casadevall, J. Dupont, D. Bouscary, 1998, Leukemia research.

[Treatment of mucositis with vitamin E during administration of neutropenic antineoplastic agents].

V. Ribrag, F. Dreyfus, G. Hazebroucq, 1994, Annales de medecine interne.

Effect of spacing intravenous bisphosphonates in patients with multiple myeloma in plateau phase

D. Borderie, C. Roux, J. Souberbielle, 2007, Leukemia.

In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes : evidence for Fas-dependent apoptosis

J. Dupont, C. Lacombe, Y. Claessens, 2002 .

A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes

E. Solary, E. Wattel, P. Fenaux, 1999, Leukemia.

SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications

M. Heuser, F. Thol, A. Ganser, 2012, Leukemia.

Prospective evaluation of the effect of deferasirox on hematologic response in transfusion‐dependent patients with low‐risk MDS and iron overload

E. Wattel, K. Laribi, C. Rose, 2018, European journal of haematology.

A phase I study of pixantrone (BBR 2778) in combination with cyclophosphamide, vincristine and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma.

P. Borchmann, J. Harousseau, R. Herbrecht, 2003 .

in MDS patients treated with AZA. Its prognostic value may be further improved by specific scoring systems established for AZA treatment such as the one we described previously.3

A. Stamatoullas, B. Quesnel, P. Fenaux, 2017 .

High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients.

P. Ravaud, S. Chevret, X. Mariette, 1993, Blood.

Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia.

J. Tamburini, N. Ifrah, C. Lacombe, 2009, Blood.

Activity of the caspase-3/CPP32 enzyme is increased in "early stage" myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro.

C. Lacombe, D. Bouscary, F. Picard, 2000, Experimental hematology.

Erythroleukaemia and RAEB-t: a same disease?

V. Leblond, K. Maloum, F. Picard, 2004, Leukemia.

Molecular detection of t(8;21)/AML1‐ETO in AML M1/M2: correlation with cytogenetics, morphology and immunophenotype

E. Macintyre, G. Flandrin, X. Troussard, 1996, British journal of haematology.

Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia

J. Tamburini, S. Maira, N. Ifrah, 2010 .

Early allogeneic transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukemia

H. Tilly, D. Blaise, J. Reiffers, 1997, Bone Marrow Transplantation.

The eukaryotic Initiating Factor 4E protein is overexpressed, but its level has no prognostic impact in acute myeloid leukaemia

J. Tamburini, M. Tulliez, S. Grabar, 2012, British journal of haematology.

Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.

P. Fenaux, M. Sébert, L. Adès, 2011, Leukemia research.

Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases.

A. Stamatoullas, P. Fenaux, L. Adès, 2011, Leukemia research.

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5 q deletion : results of a phase 2 study

A. Stamatoullas, P. Fenaux, L. Adès, 2009 .

Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.

J. Soulier, J. Cayuela, H. Dombret, 2010, Blood.

P135 Has treatment with EPO+/-G-CSF an impact on progression to AML and survival in low/int-1-risk MDS? A comparison between French-EPO patients and the IMRAW database

H. Dombret, P. Greenberg, P. Fenaux, 2007 .

Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myélodysplasies

A. Stamatoullas, B. Quesnel, P. Fenaux, 2010, Haematologica.

P-113 Revised International Prognostic Scoring System (IPSS-R) for primary treated myelodysplastic syndromes (MDS) patients: A report from the IWG-PM

M. Cazzola, F. Solé, M. L. Beau, 2013 .

Bortezomib combined with low‐dose cytarabine in Intermediate‐2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM

A. Stamatoullas, P. Fenaux, L. Adès, 2012, British journal of haematology.

A non‐randomised dose‐escalating phase II study of thalidomide for the treatment of patients with low‐risk myelodysplastic syndromes: the Thal‐SMD‐2000 trial of the Groupe Français des Myélodysplasies

P. Fenaux, M. Tulliez, A. Moreau, 2005, British journal of haematology.

Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine.

J. Maciejewski, P. Fenaux, L. Adès, 2013, Leukemia research.

Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial.

P. Fenaux, X. Thomas, X. Troussard, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM).

B. Quesnel, P. Fenaux, S. Thépot, 2013, Leukemia research.

Revised-IPSS (IPSS-R) Is a Powerful Tool to Evaluate the Outcome of MDS Patient Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience

A. Stamatoullas, B. Quesnel, P. Fenaux, 2012 .

A randomized phase II trial of azacitidine +/− epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents

A. Stamatoullas, S. Chevret, E. Wattel, 2016, Haematologica.

Outcome of Lower Risk Non Del 5q MDS after Failure of Erythropoiesis Stimulating Agents (ESA), and Impact of Post-ESA Treatment on Survival: A Retrospective European Study

A. Stamatoullas, P. Cony-Makhoul, E. Wattel, 2015 .

A randomized study of lenalidomide (LEN) with or without EPO in RBC transfusion dependent (TD) IPSS low and int-1 (lower risk) myelodysplastic syndromes (MDS) without del 5q resistant to EPO.

A. Stamatoullas, S. Chevret, P. Fenaux, 2013 .

Prognostic value of c-mpl expression in myelodysplastic syndromes.

C. Preudhomme, P. Fenaux, V. Ribrag, 1995, Leukemia.

Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure

B. Esterni, B. Quesnel, P. Fenaux, 2012, British journal of haematology.

Low-Dose Clofarabine Has Significant Activity in High-Risk Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia Post-MDS (sAML) After Azacitidine (AZA) Failure: Interim Results of the GFM Clo08 Dose Escalating Phase I/II Study (NCT0106325)

H. Dombret, A. Stamatoullas, P. Fenaux, 2011 .

with myelodysplastic syndromes: evidence for Fas-dependent apoptosis In vitro proliferation and differentiation of erythroid progenitors from patients

J. Dupont, C. Lacombe, P. Mayeux, 2013 .

Rescue of early-stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant-negative form of FADD.

C. Garrido, C. Lacombe, Y. Claessens, 2005, Blood.

Prospective Evaluation of the Effect of Deferasirox on Hematologic Response in Transfusion-Dependent Patients with Low-Risk MDS and Iron Overload: The Rythmex Study

E. Wattel, C. Rose, O. Beyne-Rauzy, 2016 .

Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy

H. Dombret, A. Vekhoff, P. Fenaux, 2005, Leukemia & lymphoma.

Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts

J. Bourhis, P. Fenaux, V. Ribrag, 2003, Leukemia.

Expression of the Evi-1 gene in myelodysplastic syndromes.

V. Ribrag, D. Bouscary, F. Dreyfus, 1995, Leukemia.

Response to Azacytidine (AZA) in MDS or AML with Del 5q : Current Results of the French ATU Program

A. Stamatoullas, E. Solary, B. Quesnel, 2008 .

Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide.

H. Dombret, A. Stamatoullas, L. Mannone, 2008, Leukemia research.

TET2 mutations in secondary acute myeloid leukemias: a French retrospective study

O. Bernard, C. Récher, A. Delmer, 2011, Haematologica.

High‐dose therapy and autologous blood stem cell transplantation in multiple myeloma: Preliminary results of a randomized trial involving 167 patients

P. Ravaud, S. Chevret, X. Mariette, 1995, Stem cells.

Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML

T. Clozel, E. Solary, C. Lacombe, 2012, Leukemia.

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort.

B. Quesnel, E. Wattel, P. Fenaux, 2012, Blood.

Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

P. Fenaux, S. Thépot, L. Adès, 2012, Leukemia research.

Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes.

A. Stamatoullas, A. Vekhoff, B. Quesnel, 2009, Leukemia research.

Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases

A. Stamatoullas, P. Fenaux, L. Adès, 2009, Leukemia.

Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS.

E. Solary, H. Tilly, E. Wattel, 1999, Advances in experimental medicine and biology.

High‐dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study

L. Mannone, P. Fenaux, L. Adès, 2006, British journal of haematology.

Leukemic phase of follicular lymphomas: an atypical presentation

M. Stern, J. Tamburini, V. Leblond, 2011, Leukemia & lymphoma.

Azacytidine in refractory or relapsed AML after intensive chemotherapy (IC): results of the French ATU Program

A. Stamatoullas, B. Quesnel, E. Wattel, 2010 .

Time Changes In Predictive Power Of MDS Prognostic Scores – Effects On Revised Scores Such As The IPSS-R, Impact Of Age

M. Cazzola, F. Solé, A. Levis, 2013 .

A Phase II Study of Post–Remission Therapy with Azacitidine (AZA) in Patients with AML Post-MDS and High-Risk MDS: A GFM Group Study.

H. Dombret, S. Chevret, P. Fenaux, 2009 .

Azacytidine (AZA) as First Line Therapy in AML: Results of the French ATU Program.

H. Dombret, A. Stamatoullas, B. Quesnel, 2009 .

101 Apoptosis and fas antigen (CD95) expression in myclodysplasia

J. D. Vos, D. Bouscary, F. Picard, 1997 .

59 Myelodysplastic syndromes with isolated neutropenia or thrombocytopenia: Are they refractory cytopenias with unilineage dysplasia? A GFM registry study

A. Stamatoullas, P. Fenaux, L. Adès, 2011 .

Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure

P. Fenaux, S. Thépot, S. Gore, 2013, Haematologica.

A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q)

P. Fenaux, L. Adès, M. Fontenay, 2013, Leukemia.

Presence of TET2 Mutation Predicts A Higher Response Rate to Azacitidine In MDS and AML Post MDS

B. Quesnel, C. Preudhomme, P. Fenaux, 2010 .

Treatment of High Risk MDS and AML Post-MDS with Azacytidine (AZA): Preliminary Results of the French ATU Program.

P. Fenaux, N. Vey, Sophie Park, 2006 .

195 Autologous bone marrow (ABMT) or peripheral blood stem cell (ABSCT) transplantation after intensive chemotherapy in myelodysplastic syndromes (MDS)

A. Stamatoullas, E. Solary, P. Fenaux, 1997 .

P-309 Low/intermerdiate-1 risk MDS treated with high-dose rHu-EPO: Hematological responses and impact on quality of life, a prospective GFM study

A. Stamatoullas, P. Fenaux, J. Delaunay, 2013 .

Factors Influencing Outcome in De Novo Myelodysplastic Syndromes Treated by Allogeneic Bone Marrow Transplantation: A Long-Term Study

C. Chastang, X. Troussard, N. Ifrah, 2002 .

Intensive Therapy of Myelodysplastic Syndromes and Secondary Leukemias: Preliminary Findings of the French Experience

E. Solary, H. Tilly, E. Wattel, 1997 .

Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire

J. Bourhis, M. Bernard, M. Labopin, 2013, European journal of haematology.

Should Immunosuppressive Therapy (IST) Be Used More Often In Lower Risk MDS

H. Dombret, P. Fenaux, L. Adès, 2010 .

Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/− Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone

S. Chevret, E. Wattel, P. Fenaux, 2010 .

Myelodysplastic Syndrome (MDS) in France: Results of a One-Week Cross-Sectional Survey on Daily Practice Management in 919 Patients by the GFM

A. Stamatoullas, B. Quesnel, P. Fenaux, 2008 .

Prognostic Factors of Response and Survival in CMML Patients Treated with Azacitidine (AZA)

J. Maciejewski, P. Fenaux, L. Adès, 2011 .

AZA In the Treatment of Therapy Related MDS and AML (tMDS/AML): a Report on 60 Patients by the Groupe Francophone Des Syndromes Myelodysplasiques (GFM)

B. Quesnel, P. Fenaux, S. Thépot, 2010 .

Azacytidine (AZA) in MDS (including RAEB-t and CMML) in Patients (pts) ≥ 80 Years: Results of the French ATU Program.

B. Quesnel, E. Wattel, P. Fenaux, 2009 .

Prognostic Factors and Response Duration in 419 MDS Treated with Erythropoietin±GCSF: The GFM Experience.

H. Dombret, A. Stamatoullas, L. Mannone, 2006 .

Is There a Role for ATRA in Combination to EPO in Lower Risk Myelodysplastic Syndrome? Preliminary Results of a Phase II Study.

A. Stamatoullas, P. Fenaux, L. Adès, 2005 .

Sequential Chemotherapy with Mitoxantrone, Etoposide and Cytarabine for Previously Treated Acute Myeloid Leukemia: EMA 86 Regimen

P. Fenaux, X. Thomas, X. Troussard, 1996 .

Lenalidomide (LEN) in INT 2 and High Risk MDS with DEL 5q. Interim Results of a Phase II Trial by the GFM.

A. Stamatoullas, P. Fenaux, L. Adès, 2007 .

Final Report of GFM-VOR2007 Study: a Phase I/II Study of Vorinostat and Low Dose Cytarabine (LDAC) for MDS Patients with Azacitidine (AZA) Failure

E. Wattel, P. Fenaux, J. Delaunay, 2012 .

Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle

Marie-Cécile Michallet, Bruno Lioure, C. Chastang, 1996 .

Erythroleukemia: a need for a new definition

F. Picard, F. Dreyfus, S. Park, 2002, Leukemia.

Erythroleukemia: a comparison between the previous FAB approach and the WHO classification.

V. Leblond, Sophie Park, F. Viguié, 2002, Leukemia research.

Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study

R. Bouabdallah, N. Brousse, C. Sebban, 2002, Leukemia.

Isodicentric/pseudoisodicentric chromosome 21 amplification in four cases of acute myelocytic leukemia or myelodysplasia.

N. Casadevall, G. Tachdjian, D. Bouscary, 2002, Cancer genetics and cytogenetics.

Detection of malignant B cells in peripheral blood stem cell collections after chemotherapy in patients with multiple myeloma.

P. Ravaud, V. Leblond, V. Ribrag, 1995, Bone marrow transplantation.

Polymyositis associated with Ki-1 lymphoma.

G. Delsol, M. Tulliez, O. Hermine, 1995, Leukemia & lymphoma.

Thrombopoietin is not responsible for the thrombocytosis observed in patients with acute myeloid leukemias and the 3q21q26 syndrome

D. Bouscary, F. Viguié, F. Picard, 1995, British journal of haematology.

Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial

M. Bernard, M. Béné, L. Fornecker, 2017, Blood Cancer Journal.

Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotype

O. Bernard, C. Elie, J. Tamburini, 2006, Leukemia.

High Response Rate and Improved Exercise Capacity and Quality of Life with a New Regimen of Darbepoetin Alfa (DAR) +/−G-CSF in Lower-Risk MDS : a Phase II Study.

A. Stamatoullas, M. Béné, P. Fenaux, 2009 .

Risk of AML Evolution In Lower Risk MDS with Del 5q Treated with or without Lenalidomide. A Report by the Groupe Francophone Des Myelodysplasies (GFM)

S. Chevret, P. Fenaux, M. Sébert, 2010 .

High Response Rate to Darbopoetin Alfa in “Low Risk” MDS : Results of a Phase II Study.

L. Mannone, P. Fenaux, C. Gardin, 2004 .

A Phase I-II Study of Vorinostat and Low Dose Cytarabine for Patients Treated for High Risk Myelodysplastic with Azacytidine Failure: The GFM-VOR2007 Study

A. Stamatoullas, E. Wattel, P. Fenaux, 2010 .

Trisenox (R) (arsenic trioxide) in patients with myelodysplastic syndromes (MDS): Preliminary results of a phase I/II study.

H. Dombret, P. Fenaux, N. Vey, 2004 .

Treatment of Lower Risk MDS with Del 5q with Lenalidomide (LEN): Results of the French ATU Program.

E. Wattel, P. Fenaux, M. Sébert, 2009 .

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.

A. Vekhoff, E. Solary, C. Preudhomme, 2011, Blood.

Pseudouveitis: A Clue to the Diagnosis of Primary Central Nervous System Lymphoma in Immunocompetent Patients

M. Tulliez, D. Grimaldi, A. Brézin, 2004, Medicine.

Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia

Marc C. Jacob, M. Boubaya, J. Rossi, 2020, Leukemia.

First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: Preliminary results of the GOELAMS 075 prospective multicenter randomized trial.

R. Gressin, E. Deconinck, N. Milpied, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML

K. Shokat, Z. Knight, J. Tamburini, 2008, Leukemia.

Blockade of p110delta isoform activity of phosphoinositide 3-kinase inhibits blast cell proliferation in acute myeloblastic leukemia.

E. Solary, B. Vanhaesebroeck, M. Béné, 2004 .

Multicentre combined chemotherapy protocol for large cell advanced non hodgkin's lymphoma

B. Asselain, M. Tulliez, J. Vilcoq, 2006, Hematological oncology.

Treatment of AML with Azacytidine (AZA): Current Results of the French ATU Program.

A. Stamatoullas, B. Quesnel, L. Mannone, 2007 .

Aplastic anemia responsive to cyclosporine complicating the evolution of polycythemia vera.

N. Casadevall, D. Bouscary, F. Viguié, 1999, Leukemia & lymphoma.

Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.

J. Tamburini, N. Ifrah, C. Lacombe, 2008, Blood.

Coronavirus 229E-Related Pneumonia in Immunocompromised Patients

A. Cariou, F. Pène, P. Lebon, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes.

A. Stamatoullas, E. Wattel, P. Fenaux, 2004, The hematology journal : the official journal of the European Haematology Association.

Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia.

P. Fenaux, E. Archimbaud, V. Leblond, 1991, Blood.

Performance of Serum Biomarkers for the Early Detection of Invasive Aspergillosis in Febrile, Neutropenic Patients: A Multi-State Model

B. Farley, A. Vekhoff, S. Leprêtre, 2013, PloS one.

Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM)

A. Baruchel, H. Tilly, D. Blaise, 2000, Bone Marrow Transplantation.

Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study.

M. Béné, C. Récher, F. Bauduer, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of Adult T-Cell Leukemia-Lymphoma with Zidovudine and Interferon Alfa

E. Macintyre, V. Leblond, A. Bazarbachi, 1995 .

The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation.

B. Viollet, J. Tamburini, M. Foretz, 2010, Blood.

hpttg, a human homologue of rat pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG

F. Ramos-Morales, F. Romero, R. Rios, 1998, Oncogene.

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.

Claude Preudhomme, Daniel Birnbaum, Olivier Kosmider, 2012, Blood.

IMPACT OF T-CELL DEPLETION ON OUTCOME OF ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR STANDARD-RISK LEUKAEMIAS

D. Blaise, V. Leblond, N. Ifrah, 1987, The Lancet.

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

B. Quesnel, C. Preudhomme, P. Fenaux, 2011, Leukemia.

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia

D. Birnbaum, E. Solary, W. Vainchenker, 2009, Haematologica.

Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes

M. Béné, M. Fontenay, I. Radford‐Weiss, 2013, Leukemia.

B. Groner, F. Gouilleux, V. Gouilleux-Gruart, 1996 .

B. Groner, F. Gouilleux, V. Gouilleux-Gruart, 1996, Blood.

Adult Acute Lymphoblastic Leukemia — Results of the French AALL 87 Protocol with Different Strategies of Postremission Therapy

H. Dombret, A. Delannoy, C. Sebban, 1994 .

Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma

C. Lacombe, Y. Claessens, F. Pène, 2002, Oncogene.

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion

A. Stamatoullas, P. Cony-Makhoul, S. Chevret, 2016, Leukemia.

Lenalidomide with or without Erythropoietin in transfusion dependent erythropoiesis-stimulating agent-refractory lower risk MDS without 5 q deletion Running title : Lenalidomide in transfused non del 5 q low risk MDS

Stanislas, Taksin, A. Stamatoullas, 2015 .

A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse

P. Chevallier, M. Béné, J. Tamburini, 2013, Leukemia.

IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia.

F. Agou, J. Tamburini, V. Baud, 2010, Blood.

B kinase overcomes PI 3 K / Akt and ERK / MAPK to control FOXO 3 a activity in acute myeloid leukemia

F. Agou, J. Tamburini, V. Baud, 2010 .

Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody

J. Tamburini, N. Ifrah, C. Lacombe, 2010, Haematologica.

Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia

E. Solary, B. Vanhaesebroeck, N. Ifrah, 2005 .

c-mpl expression in hematologic disorders.

C. Prudhomme, B. Quesnel, D. Bouscary, 1995, Leukemia & lymphoma.

Essential role for the p 110 δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia

E. Solary, B. Vanhaesebroeck, N. Ifrah, 2005 .

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study.

A. Stamatoullas, P. Fenaux, L. Adès, 2009, Blood.

Six epitopes reacting with human cytotoxic CD8+ T cells in the central region of the HIV-1 NEF protein.

B. Guy, M. Kieny, J. Levy, 1991, Journal of immunology.

Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.

H. Dombret, M. Dennis, P. Fenaux, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes.

P. Vyas, E. Solary, C. Garrido, 2012, Blood.

Glutathione system, topoisomerase II level and multidrug resistance phenotype in acute myelogenous leukemia before treatment and at relapse.

A. Faussat, V. Ribrag, L. Massaad-Massade, 1997, Anticancer research.

Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation.

S. Chevret, I. Yakoub-Agha, E. Wattel, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia.

E. Solary, B. Vanhaesebroeck, N. Ifrah, 2005, Blood.

Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion.

A. Stamatoullas, E. Solary, S. Chevret, 2016, Blood.

Prognostic score including gene mutations in chronic myelomonocytic leukemia.

D. Birnbaum, T. Haferlach, E. Solary, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autologous stem cell transplantation in patients who object to a blood transfusion: contribution of new pharmacological haematopoiesis support

J. Tamburini, D. Bouscary, Sophie Park, 2013, British journal of haematology.

Time-dependent changes in mortality and transformation risk in MDS.

M. Cazzola, F. Solé, M. L. Le Beau, 2016, Blood.

High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.

P. Ravaud, S. Chevret, X. Mariette, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A spontaneous remission of lymphoid blast crisis in chronic myelogenous leukaemia following blood transfusion and infection

G. Flandrin, I. Radford‐Weiss, O. Hermine, 1994, British journal of haematology.

BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.

D. Birnbaum, S. Miyano, Y. Shiraishi, 2013, Blood.

Donor bone marrow treatment with T101 Fab fragment-ricin A-chain immunotoxin prevents graft-versus-host disease.

J. Reiffers, G. Laurent, E. Gluckman, 1989, Bone marrow transplantation.

An antigenic peptide of the HIV‐1 NEF protein recognized by cytotoxic T lymphocytes of seropositive individuals in association with different HLA‐B

B. Guy, M. Kieny, J. Levy, 1989, European journal of immunology.

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.

A. Stamatoullas, K. Götze, P. Cony-Makhoul, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia

J. Tamburini, S. Guichard, P. Auberger, 2012, Leukemia.

No Benefit of First-Line Rituximab (R) - High-Dose Therapy (R-HDT) Over R-CHOP14 for Young Adults with Diffuse Large B-Cell Lymphoma. Preliminary Results of the GOELAMS 075 Prospective Multicentre Randomized Trial

R. Gressin, E. Deconinck, H. Maisonneuve, 2010 .

Thrombocytemia and abnormal megakaryopoiesis associated with abnormality of chromosome 1p34 in myelodysplastic syndromes.

D. Bouscary, F. Viguié, F. Picard, 1996, Leukemia.

P-104 Outcomes by IPSS-R in lenalidomide-treated patients with IPSS low-/Int-1-risk MDS With del(5q) in MDS-003 and MDS-004: A retrospective analysis

M. Cazzola, P. Greenberg, G. Garcia-Manero, 2013 .

Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.

B. Esterni, B. Quesnel, P. Fenaux, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90y-Epratuzumab Tetraxetan Following R-CHOP in Elderly DLBCL Patients: A Lysa Phase II Prospective Trial

P. Moreau, R. Gressin, E. Deconinck, 2012 .

Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients

J. Tamburini, P. Morel, A. Delmer, 2005, Leukemia.

Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia

J. Tamburini, S. Maira, N. Ifrah, 2010, Clinical Cancer Research.

Rituximab-induced life-threatening coagulopathy occurring in a patient with Waldenström macroglobulinemia treated with fludarabine, cyclophosphamide, and rituximab combination

J. Tamburini, D. Bouscary, Sophie Park, 2010, Leukemia & lymphoma.

Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).

B. Quesnel, P. Fenaux, S. Thépot, 2010, Blood.

Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3‐ITD molecular status for cytogenetically normal AML patients: A GOELAMS study

P. Chevallier, M. Béné, C. Récher, 2012, American journal of hematology.

Age-adapted induction treatment of acute lymphoblastic leukemia in the elderly and assessment of maintenance with interferon combined with chemotherapy. A multicentric prospective study in forty patients

R. Bouabdallah, P. Cony-Makhoul, A. Delannoy, 1997, Leukemia.

Peripheral blood stem cell collection and autografting in high risk lymphomas.

V. Leblond, V. Ribrag, A. Goy, 1992, Bone Marrow Transplantation.

Azacitidine in untreated acute myeloid leukemia: A report on 149 patients

H. Dombret, A. Stamatoullas, B. Quesnel, 2014, American journal of hematology.

Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients.

Philippe Broët, Bruno Lioure, Patrick Mayeux, 2007, Blood.

Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS.

M. Béné, J. Reiffers, C. Récher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Contamination of peripheral blood by monoclonal B cells following treatment of multiple myeloma by high‐dose chemotherapy

F. Dreyfus, J. Melle, M. Quarre, 1993, British journal of haematology.

patients favorable prognostic factor in de novo acute myelogenous leukemia Constitutive phosphoinositide 3-kinase/Akt activation represents a

C. Elie, J. Tamburini, V. Ugo, 2013 .

Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Société Française de Greffe de Moelle.

C. Chastang, J. Reiffers, X. Troussard, 1996, Blood.

Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial.

H. Dombret, A. Stamatoullas, A. Vekhoff, 2004, Blood.

p-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes

V. Viallon, F. Porteu, E. Frisan, 2010, Haematologica.

Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.

H. Dombret, A. Stamatoullas, E. Wattel, 2006, Haematologica.

Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study

M. Bernard, M. Béné, L. Fornecker, 2020, Leukemia.

Refractory Thrombocytopenia and Neutropenia: a Diagnostic Challenge

P. Fenaux, F. Dreyfus, E. Gyan, 2015, Mediterranean journal of hematology and infectious diseases.

Salvage therapy of Autoimmune Thrombocytopenic Purpura revealing non‐Hodgkin Lymphoma by the thrombopoietin receptor agonist romiplostim

T. Molina, J. Tamburini, O. Hermine, 2012, British journal of haematology.

Lack of evidence of an association between HHV-8 and multiple myeloma

V. Calvez, P. Ravaud, N. Dupin, 1998, Leukemia.

High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B‐cell lymphoma in first relapse: results of the R‐NIMP GOELAMS study

R. Gressin, K. Laribi, D. Damotte, 2013, British journal of haematology.

Positive Impact of Iron Chelation Therapy (CT) on Survival in Regularly Transfused MDS Patients. A Prospective Analysis by the GFM.

A. Stamatoullas, B. Quesnel, P. Fenaux, 2007 .

RECONSTITUTION OF CYTOTOXIC T LYMPHOCYTE ACTIVITY: Following Allogeneic Bone Marrow Transplantation In Man

J. Levy, M. Bagot, C. Cordonnier, 1987, Transplantation.

High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM

A. Stamatoullas, M. Béné, P. Fenaux, 2013, Annals of Hematology.

N. Casadevall, O. Legrand, D. Bouscary, 2000, British journal of haematology.

Groupe neoplasms to myelodysplastic syndrome or acute myeloid leukemia by Treatment of progression of Philadelphia-negative myeloproliferative

B. Quesnel, P. Fenaux, S. Thépot, 2010 .

Thalidomide for the Treatment of Low Risk Myelodysplasia.

A. Stamatoullas, P. Fenaux, A. Aouba, 2004 .

Drug resistance mechanisms in chronic lymphocytic leukemia.

A. Faussat, V. Ribrag, F. Dreyfus, 1996, Leukemia.

Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry.

J. Tamburini, N. Ifrah, C. Lacombe, 2006, Haematologica.

Intensified-dose (4 gm/m2) cyclophosphamide and granulocyte colony-stimulating factor administration for hematopoietic stem cell mobilization in refractory rheumatoid arthritis.

M. Dougados, M. Breban, D. Bouscary, 1999, Arthritis and rheumatism.

Pure red cell aplasia associated with myelodysplastic syndromes

F. Viguié, F. Picard, F. Dreyfus, 2000, Leukemia.

BCOR and BCORL 1 mutations in myelodysplastic syndromes and related disorders

D. Birnbaum, S. Miyano, Y. Shiraishi, 2013 .

Long-term remission of an EBV-positive B cell lymphoproliferative disorder associated with rheumatoid arthritis under methotrexate with anti-CD20 monoclonal antibody (Rituximab) monotherapy

M. Tulliez, D. Bouscary, F. Dreyfus, 2002, Leukemia.

CORRESPONDENCE Lack of evidence of an association between HHV-8 and multiple myeloma

V. Calvez, P. Ravaud, P. Koeffler, 1998 .

Arsenic Trioxide (AS2O3) Therapy for Relapsed Acute Promyelocytic Leukemia (APL): Comparison with a Historic Control Combining All-Trans Retinoic Acid (ATRA) Plus Intensive Chemotherapy.

A. Stamatoullas, M. Bernard, P. Fenaux, 2005 .

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents

A. Stamatoullas, P. Fenaux, L. Adès, 2013, Leukemia.

In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis.

J. Dupont, C. Lacombe, Y. Claessens, 2002, Blood.

Constitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p110δ mutations

J. Tamburini, N. Ifrah, P. Cornillet‐Lefèbvre, 2006, Leukemia.

Fluorescence in situ hybridization analysis of minute marker chromosomes in leukemia with monosomy 7.

R. Zittoun, F. Viguié, F. Dreyfus, 1995, Leukemia.

Association of TET2 Alterations with NPM1 Mutations and Prognostic Value in De Novo Acute Myeloid Leukemia (AML).

J. Soulier, J. Cayuela, H. Dombret, 2009 .

Elevated thrombopoietin serum concentrations in myelodysplasias.

C. Lacombe, D. Bouscary, F. Dreyfus, 1998, Platelets.

1 mTORC 1 inhibition activates PI 3 K / Akt by up-regulating IGF-1 R signaling in acute myeloid leukemia : rational for therapeutic inhibition of both pathways

J. Tamburini, N. Ifrah, C. Lacombe, 2007 .

therapeutic inhibition of both pathways factor-1 receptor signaling in acute myeloid leukemia: rationale for phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth Mammalian target of rapamycin (mTOR) inhibition activates

J. Tamburini, N. Ifrah, C. Lacombe, 2013 .

Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia

J. Tamburini, N. Ifrah, P. Mayeux, 2010 .

J. Tamburini, N. Ifrah, C. Lacombe, 2008, Blood.

Mutation in TET2 in myeloid cancers.

J. Soulier, W. Vainchenker, O. Bernard, 2009, The New England journal of medicine.

Prognostic score including gene mutations in chronic myelomonocytic leukemia.

D. Birnbaum, T. Haferlach, E. Solary, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of the association of lenalidomide to erythropoiesis-stimulating agents in del (5q) MDS patients refractory to single-agent lenalidomide

F. Viguié, F. Dreyfus, S. Park, 2010, Leukemia.

Azacitidine in untreated acute myeloid leukemia: A report on 149 patients

H. Dombret, A. Stamatoullas, B. Quesnel, 2014, American journal of hematology.

The eukaryotic Initiating Factor 4E protein is overexpressed, but its level has no prognostic impact in acute myeloid leukaemia

J. Tamburini, M. Tulliez, S. Grabar, 2012, British journal of haematology.

B cells from leukemic patients are relatively resistant to in-vitro EBV transformation.

J. Levy, M. Bagot, F. Picard, 1986, Leukemia research.

Thrombopoietin stimulates cortactin translocation to the cytoskeleton independently of tyrosine phosphorylation.

F. Dreyfus, V. Duprez, J. Melle, 2001, The Biochemical journal.

Protein Synthesis Escapes mTORC1 Control and Constitutes a Promising Therapeutic Target in Acute Myeloid Leukemia.

J. Tamburini, N. Ifrah, C. Lacombe, 2008 .

Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.

H. Dombret, A. Stamatoullas, E. Wattel, 2006, Haematologica.